COMPANY:

BPGbio

"The featured research spans BPGbio’s oncology pipeline and precision medicine efforts, including mechanistic and clinical insights into BPM31510, a first-in-class oxidized CoQ10 nanodispersion that has demonstrated encouraging results in multiple clinical trials in oncology and other mitochondrial disease areas, and BRG399, a novel microtubule-binding agent that induces immunogenic cell death (ICD). These presentations reinforce BPGbio’s leadership in reprogramming cancer metabolism and targeting mitochondrial dysfunction to drive therapeutic advancement."

"Highlights from posters include: New data further validating the mitochondrial-centric effect of BPM31510 on the immune system. In addition to its direct cell-killing effect on tumor cells, data supports the potential use of BPM31510 in the intersection of tumor immunology and tumor metabolism; BPGbio’s NAi Platform coupled with a subsequent deep learning algorithm implemented on BRG399, a novel pan-cancer drug candidate, can improve efficiency in drug development by rapidly predicting anti-cancer efficacy in silico before conducting resource intensive preclinical experiments."

"BPGbio, Inc...announced the commercial launch of the NAi (pronounced 'nye') Interrogative Biology® Platform, the company’s AI-powered platform technology for broad scale development and repurposing of drugs, identification of diagnostic biomarkers, and health analytics...'The NAi Interrogative Biology Platform was developed to embrace the true story of patient biology by using mathematics and technology to de-risk therapeutics and diagnostics development,'..."

"BPGbio, Inc...announced that it has signed a collaborative agreement with Grupo Terralpe, Inc., a renowned private investment group based in Mexico City and Boston, Mass. Together, the companies will commercialize the pstateDx™ test, BPGbio’s prostate cancer diagnostic test, in Mexico."